<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>JOURNAL VIROLOGY, 1993, p. 2496-2502                                                                                    Vol. 67,  5 <br /> 0022-538X/93/052496-07$02.00/0 <br /> Copyright &#194;&#169;D 1993, American Society Microbiology <br />  <br />  <br />             Dominant Negative Mutants Human T-Cell Leukemia <br />                Virus Type Rex Human Immunodeficiency <br />                 Virus Type 1 Rev Fail Multimerize Vivo <br />                                           HAL BOGERD WARNER C. GREENEt* <br />                 Department Medicine Department Microbiology Immunology, Howard Hughes <br />                     Medical Institute, Duke University Medical Center, Durham, North Carolina 27710 <br />                                            Received 12 October 1992/Accepted 18 January 1993 <br />  <br />              Human T-cell leukemia virus type (HTLV  Rex human immunodeficiency virus type 1 (HIV-1) Rev <br />           essential gene products required replication pathogenic human retroviruses. Rex <br />           Rev act posttranscriptional level binding highly structured RNA-response elements,           Rex-response element HTLV Rev-response element HIV-1. Using sensitive vivo assay           protein-protein interaction, demonstrate HTLV Rex HIV-1 Rev proteins readily form <br />           homomultimeric complexes absence cognate RNA-response elements fail form heteromul- <br />           timeric complexes  Dominant negative mutations identified rex rev <br />           genes presumably specify critical activation effector domain viral transactivators. <br />           Surprisingly, dominant negative mutants Rex Rev fail interact vivo. findings raise           possibility binding nonfunctional monomers functional multimers underlies           transdominant phenotype Rex Rev mutants.  likely assembly           functional stable multimers Rex Rev vivo depend intrinsic multimerization <br />           domains proteins binding bridging cellular cofactor related activation <br />           domains present viral transactivator. <br />  <br />    Type human T-cell leukemia virus (HTLV  type 1                    functional effects directly binding highly structured, <br /> human immunodeficiency virus (HIV-1) correspond                           unrelated, RNA response elements (1, 3, 5, 8, 15, 20, 21, <br /> pathogenic human retroviruses produce distinctly dif-                   32, 52, 55, 57). Rex-response element (RexRE) ferent clinical disease states. HTLV corresponds                    located 3&apos; long terminal repeat HTLV (20, 45, 49), <br /> etiologic agent adult T-cell leukemia, neoplastic                   Rev-response element (RevRE) positioned <br /> proliferation mature activated CD4+ T lymphocytes                     env coding region HIV-1 (9, 18, 30, 42). <br /> (38, 51, 56). addition, HTLV recently linked                   Surprisingly, despite general lack sequence homol- tropical spastic paraparesis HTLV associated                    ogy, HTLV Rex protein capable functionally <br /> elopathy, progressive demyelinating neuropathic syn-                       replacing Rev HIV-1 replicative life cycle (11, 40). <br /> drome bearing superficial resemblance multiple sclerosis                 Rex shown bind HIV-1 RevRE <br /> (14, 37). contrast, HIV-1 infection associated                high-affinity site distinct recognized Rev (5, <br /> fatal condition AIDS, characterized progressive                  48). contrast, HIV-1 Rev fails replace function CD4+ T-cell death T-cell transformation (4, 10,                  Rex, indicating nonreciprocal pattern genetic comple- <br /> 13). HTLV type C oncogenic retrovirus                  mentation (1, 11, 40). <br /> HIV-1 prototypical human member lentivirus                        precise biochemical mechanism underlying bio- <br /> family, viruses utilize strikingly similar strate-             logical effects Rex Rev remains unknown. gies regulated expression structural (gag               proteins proposed act inhibiting <br /> env) enzymatic (pol) gene products. Specifically,                   spliceosome function (6), allowing nuclear export viruses encode essential nuclear trans-regulatory proteins,                  unspliced singly spliced viral mRNAs default, Rex HTLV Rev HIV-1, act posttranscrip-                      alternatively selectively activating nuclear transport <br /> tionally promote cytoplasmic expression translation                   pathway promotes cytoplasmic delivery translation unspliced singly spliced species viral mRNAs uniquely encode gag-pol env gene products,                      incompletely processed viral mRNAs (18, 19, 30). <br /> respectively  reviews, references 17 41                      Functional analyses extensive series missense <br /> references . absence Rex Rev,                    mutations HTLV rex HIV-1 rev genes <br /> viral mRNAs remain sequestered nucleus,                    revealed presence functional  degraded completely spliced yield physi-                  mains proteins (27, 31, 39, 53). domain corre- <br /> cally smaller class viral mRNAs encode various                   sponds arginine-rich motif mediates RNA binding <br /> regulatory gene products (tax rex HTLV tat, rev,                 nuclear localization. Mutations domain yield nef HIV-1) (20, 25, 29). Rex Rev exert                      recessive negative mutants Rex Rev lack <br />                                                                              biological activity coexpressed fail interfere <br />                                                                              function wild-type counterparts. second, <br />   * <br />     Corresponding author.                                                    C-terminal domain corresponds presumed activa- <br />   t Present address: Gladstone Institute Virology Immunol-            tion effector region mutated leads ogy, University California, San Francisco, San Francisco General          dominant negative class mutants lack <br /> Hospital, P.O. Box 419100, San Francisco, CA 94141-9100.                     biological activity interfere function                                                                       2496 <br />  VOL. 67, 1993                                              FAILURE Rex Rev MUTANTS MULTIMERIZE                                 2497 <br />  <br /> wild-type transactivator. expected, dominant neg-                      TABLE 1. CAT activities Rex mutants <br /> ative mutants Rex Rev retain capacity specif-         Rex            Altered amino                              CAT activity&apos; <br /> ically engage RNA response elements, argi-          protein              acids               Phenotype           (% WT) rich RNA binding domains unaltered (5, 28). <br />    Previous studies suggested presence      wT                                         wT                   100 <br /> domain HIV-1 Rev protein mediates multimeriza-          M4               33-35   (DTQ)             WT              113.5 + 7.0 <br /> tion transactivator protein (27, 28, 36, 58).          M5              43, 44   (YK)              WT               86.9 + 9.4 <br /> domain immediately flanks arginine-rich motif, mu-          M6              59, 60   (YI)              DNb              11.6 + 2.7 <br />                                                                     M7              64, 65   (YW)              DN               19.8 &#194;&#177; 3.8 <br /> tations shown lead loss Rev            M8              72, 73   (RS)              WT               97.0 + 17.5 <br /> function variably recessive negative             M1o           101, 102   (EP)              WT              100.0 &#194;&#177; 17.2 <br /> weakly dominant negative functional phenotype (28).             M13           119-121    (TFH)             DN               10.5 &#194;&#177; 4.3  precise role protein-protein interaction plays    M14           134-136    (SEM)             WT              107.4 &#194;&#177; 16.5 vivo biological action Rex Rev remains            Dominant negative HTLV Rex mutants fail multimerize vivo. incompletely understood. study, used         GAIA-Rex Rex (missense wild type [WTl)-VP16 expression vectors <br /> vivo assay protein-protein association, modified      cotransfected COS cells pG5BCAT reporter plasmid described Fields Song yeast cells (12), study   assayed induction CAT enzyme activity. level CAT expression ability HTLV Rex HIV-1 Rev proteins            obtained cotransfection combinations GAL4-Rex Rex-VP16 <br />                                                                    assigned value 100%. Rex mutants M4, M5, M8, M10, M14 retain <br /> form homo- heteromultimeric complexes living cells          wild-type biological activity, M6, M7, M13 mutants correspond absence cognate RNA response elements.          dominant negative mutants (39). Data presented correspond mean demonstrate Rex Rev readily form homomul-             levels + standard errors means obtained independent <br /> timers vivo fail assemble heteromultimers        transfection experiments. <br />                                                                      b DN, dominant negative.  dominant negative muta- <br /> tions Rex Rev completely abrogate vivo protein-protein association.  findings <br /> suggest protein-protein interactions inextrica-     quence 78-residue acidic activation domain bly linked biological function Rex Rev         herpes simplex virus VP16 gene supplemented C-ter- mechanism transdominant inactivation               minal stop codon (43, 50) ligated frame unique <br /> involve blockade critical protein-protein inter-      extreme 3&apos; BglII sites pcRex M18 (39), pcRev M14 (27), <br /> actions.                                                           pc TaxM52 (47). mutations located                                                                    near C terminus natural protein, mutant <br />                MATERLALS METHODS                               retains wild-type biological activity. <br />                                                                       addition pcRex-VP16 expression vector    vivo assay protein-protein interaction. ability    encodes 181 amino acids Rex followed HTLV Rex HIV-1 Rev proteins associate vivo         78-residue activation domain VP16, series C-terminal studied using modified version yeast GAL4-         deletions Rex fused VP16 activation domain, <br /> based assay described Fields Song (12). brief,     generating pcRex(1-118)-VP16, pcRex(1-133)-VP16, <br /> Rex Rev cDNAs fused DNA binding             pcRex(1-161)-VP16 expression vectors, respectively. <br /> domain GAL4 (residues 1 147) (44) strong              pcRex(missense)-VP16 expression vectors  <br /> transcriptional activation domain herpes simplex            structed excision wild-type DNA fragment (HindIII- <br /> virus-derived VP16 gene product (residues 413 490) (50).        ClaI ClaI-BglII) Rex-VP16 expression vector, various expression vectors transfected        followed insertion equivalent mutated DNA <br /> COS cells, combination        previously described Rex analog, M4, M5, M6, M7, <br /> presence chloramphenicol acetyltransferase (CAT)            M8, M10, M13, M14 (39) (Table 1). pcRev-VP16 <br /> reporter plasmid pG5BCAT, containing binding sites        vector encodes initial 111 amino acids Rev followed GAL4 (43). Effective protein-protein interaction         activation domain VP16, pcTax-VP16 vector <br /> Rex Rev predicted spatially juxtapose GAL4            encodes 351 amino acids HTLV-1 Tax protein <br /> DNA binding domain VP16 transcriptional activation             followed activation domain VP16. <br /> domain encoded different plasmids, turn               Cell transfections. COS monkey kidney cells cotrans- <br /> leads stimulation pG5BCAT reporter plasmid.              fected 2 ,ug CAT reporter plasmid pG5BCAT, 4 ,ug    GALA chimeric expression plasmids. produce vari-         GALA chimeric expression plasmid, 4 ,ug VP16 <br /> ous chimeric GAL4 expression vectors, coding se-               chimeric expression plasmid, using DEAE-dextran followed <br /> quences Rex Rev amplified polymerase            incubation chloroquine dimethylsulfoxide shock <br /> chain reaction ligated frame downstream        (46). needed, pCMV-IL2 plasmid DNA (7) added 147 codons yeast GALA transcription factor contained        maintain constant DNA concentration transfections. pSG424 expression vector (44). addition       Approximately 48 h transfection, cell extracts entire coding sequence Rex (amino acids 1 189),        prepared tested CAT activity, using phase <br /> N-terminal deletions Rex (amino acids 32 189, 51          separation assay described Neumann et al. (35). <br /> 189, 71 189) ligated BamHI-SacI fragments             Western immunoblotting chimeric proteins. confirm plasmid pSG424 produce GAL4-Rex(32-189),               production protein expression vector, Western <br /> GALA-Rex(51-189), GAL4-Rex(71-189) expression vec-             blotting studies performed COS cells transfected <br /> tors. Similarly, complete coding sequence Rev               4 ,ug plasmid DNA; 48 h later, cultures (codons 1 116) missense mutations Rev, M4          lysed radioimmunoprecipitation buffer (150 mM NaCl, <br /> (28), M28, M33 (27)  Table 2), ligated             1.0% Nonidet P-40, 0.5% deoxycholate, 0.1% sodium dode- <br /> KpnI-SacI fragments pSG424 vector.                        cyl sulfate [SDS], 50 mM Tris [pH 8.0J) (29), extract <br />   VP16 chimeric expression plasmids. produce second         proteins separated SDS-10% polyacrylamide gels. <br /> set chimeric VP16 expression vectors, coding se-            proteins transferred nitrocellulose filters <br />  2498       BOGERD GREENE                                                                                                      J. VIROL. <br />  <br />                                                                                 n 120 <br />                                                                                 a0   100 <br />            C   25                                                                        0 <br />  <br />        o       20                                                               2&quot;       60 <br />                                                                                 o        40 <br />  <br />        0 <br />                                                                                 0B 20 <br />                                                                                      0       0 <br />                 5 <br />  <br />  <br />  <br />  <br />                                                                           FIG. 2. Evidence sequences required vivo multimer- <br />                                                                         ization HTLV Rex protein located residues 32 <br />   FIG. 1. Evidence HTLV Rex protein forms apparent           133. chimeric Rex deletion expression vectors homomultimeric complexes vivo absence RexRE.           designed resultant protein contained functional <br /> COS cells cotransfected various combinations           nuclear localization signal. N-terminal deletion constructs GAL4 VP16 chimeric expression vectors indicated              fused GAL4, allowing utilization GAL4 nuclear localization <br /> pG5BCAT, cultures assayed CAT enzyme activity          signal, Rex C-terminal deletions fused VP16 <br /> 48 h later. level CAT activity resulting coexpression   activation utilized native Rex nuclear localization GAL4 Rex-VP16 used baseline. Data presented           signal. COS cells cotransfected GAL4-Rex correspond mean fold stimulation levels + standard errors     Rex(C-terminal deletion)-VP16 GAL4-Rex(N-terminal deletion) means obtained independent transfection experiments.        Rex-VP16. level transactivation resulting                                                                         coexpression GAL4-Rex Rex-VP16 assigned value                                                                         100%. Data presented correspond mean fold stimulation incubated specific anti-Rex (39), anti-Rev              levels &#194;&#177; standard errors means obtained indepen- <br /> (27), anti-Tax (47) antisera (1:1,000 dilution) followed          dent transfection experiments. <br /> 1251I-protein  Immunoreactive proteins visual- <br /> ized autoradiography. <br />                                                                         series revealed final 56 amino acids Rex [C-Rex(1- <br />                            RESULTS                                      133)] entirely dispensable vivo assembly,                                                                         deletion 15 additional carboxy amino acids [C-Rex(1-118)] <br />   shown Fig. 1, expression VP16-Rex vector                 markedly attenuated protein-protein interaction (Fig. 2). conjunction GAL4 expression vector                 studies mapped extreme boundaries produced significant activation pG5BCAT reporter              Rex domain(s) required vivo protein-protein associa- <br /> plasmid.  coexpression Rex-VP16                      tion segment residing residues 32 133. <br /> GAL4-Rex plasmids led nearly 30-fold increase CAT                  Strikingly, boundaries domain involved vivo <br /> activity. transcriptional activation dependent              multimerization Rex appeared coincident presence GALA DNA binding domain                    domain Rex required biological activity (22). VP16 activation domain, cotransfection vectors encod-             investigate finding, series previously char- <br /> ing Rex Rex-VP16 GAL4-Rex Rex failed                      acterized Rex missense mutations domain (39) <br /> produce significant stimulation (Fig. 1). observed               tested context VP16-Rex expression vector. <br /> creases CAT expression reflected specific Rex-Rex             missense mutants included dominant negative <br /> protein interaction, coexpression GAL4-Rex                   mutations inactivated Rex effector domain Rev-VP16 HTLV Tax-VP16 produced signifi-                 control point mutations scattered stimulation. note, Rex-Rex interaction occurring            region failed alter resultant biological activity trans appeared quite stable, level CAT activity            Rex. dominant negative point mutants obtained consistently greater                Rex displayed markedly reduced capacity associate measured GAL4-VP16 vector, links cis              vivo, missense mutants retaining <br /> DNA binding domain GALA transcriptional                      wild-type biological activity displayed normal activity (Table <br /> activation domain VP16 (43). Similar stimulatory effects             1). Importantly, inactive dominant-negative obtained transcriptional activation domain             Rex fusion proteins expressed stable manner, NF-KBp65 (2) substituted VP16 component,                    assessed Western blotting (Fig. 3). <br /> indicating general nature stimulatory effects.                vivo protein-protein interaction HIV-1 Rev <br />    identify sequences Rex required vivo           protein similarly studied (Fig. 4). Coexpression protein-protein interaction, series expression vectors             GAL4-Rev Rev-VP16 vectors induced approximately encoding various N- C-terminal deletions tested                 eightfold activation CAT activity compared (Fig. 2). vectors specifically designed ensure            various negative controls. Rex, response  chimeric protein retained functional nuclear                quired coexpression GAL4 DNA binding domain <br /> localization signal. chimeric protein composed Rex                 VP16 activation domain, linked cis Rev. <br /> residues 32 189 retain multimerization             response detected following expression DNA <br /> activity (Fig. 2). contrast, deletion 50 70 N-terminal         binding domain GAL4 Rev-VP16 GAL4-Rev <br /> residues Rex [N-Rex(51-189) N-Rex(71-189)] produced               plasmid (Fig. 4).  heteromultimerization partial nearly complete loss vivo multimerization            Rev Rex Tax observed. note, CAT activity <br /> activity (Fig. 2). Similar analyses C-terminal deletion          induced GAL-4 Rev Rev-VP16 combinations  VOL. 67, 1993                                                  FAILURE Rex Rev MUTANTS MULTIMERIZE                                  2499 <br />  <br />                       1   2   3 4     5   6    7   8                                 TABLE 2. CAT activities Rev mutants <br />                 68-                                                                      Change WT <br />  <br />                 43- <br />                                                                          Rev <br />                                                                         protein    wI&apos;        amtered <br />                                                                                               amino       Mutation <br />                                                                                                                       Phenotype      CAT  activitya <br />                                                                                                                                       (% wI&apos;) <br />                                                                                                acids <br />                 30- <br />                                                                          WT                                     WT                   100 <br />                                                                          M4       YQSN 23, 25, 26          DQDL      DNb (weak)        6.7 &#194;&#177; 2.5 <br />                 18-                                                      M28      L    81                          DN                0.6 0.6 <br />   FIG. 3. Western blotting analysis Rex-VP16 fusion protein       M33      DC   84, 85              NS        WT               98.0 &#194;&#177; 9.6 <br /> expression COS cells. Shown results Rex M4 (lane 1), Rex       Dominant negative HIV Rev mutants fail multimerize vivo. M5 (lane 2), Rex M6 (lane 3), Rex M7 (lane 4), Rex M8 (lane 5), Rex     GAL4-Rev (missense wild type [WT]) Rev-VP16 expression vectors <br /> M10 (lane 6), Rex M13 (lane 7), Rex M14 (lane 8). Functional        cotransfected COS cells pG5BCAT reporter plasmid results Rex mutants presented Table 1. Sizes       assayed induction CAT enzyme activity. level CAT <br /> indicated kilodaltons.                                               expression obtained combinations GAL4-Rev Rev-VP16 <br />                                                                         plasmids assigned value 100%. Rev mutant M33 retains wild-type <br />                                                                         biological activity, M4 multimerization domain mutant M28 <br />                                                                         leucine-rich activation domain mutant displayed weak strong recessive <br />                                                                         negative dominant negative phenotypes, respectively (27, 28, 31). Data <br /> consistently 25 30% response obtained               presented correspond mean levels + standard errors means <br /> GAL-4 Rex Rex-VP16 8 10% response                obtained independent transfection experiments. <br /> obtained GAILA-VP16 plasmid,                    b DN, dominant negative. <br /> domains linked cis. <br />   determine previously described activation multimerization domains Rev required                                            DISCUSSION <br /> vivo protein-protein interaction, previously described <br /> missense mutations Rev tested fusion proteins                  HTLV Rex HIV-1 Rev proteins subserve func- DNA binding domain GALA (Table 2) (27, 28,                  tionally similar roles replicative life cycles 31). wild-type Rev Rev missense mutant (M33)                 human retroviruses. Specifically, essential <br /> altered near leucine-rich activation              regulatory proteins promote cytoplasmic expression main readily interacted vivo. sharp contrast, GALA-             translation incompletely spliced family viral mRNAs <br /> Rev chimera containing dominant negative M28 mutation               uniquely encode structural enzymatic proteins <br /> altered leucine-rich activation domain Rev                needed assembly infectious virions (reviewed failed associate vivo.  residue mutation          references 17 41).  action Rev (M4) N-terminal component                 proteins appears dependent direct binding highly <br /> multimerization domain (28) (amino acids residues 23 31              structured RNA response elements (1, 3, 5, 8, 15, 20, 21, 32, 54 57) produced diminished CAT expression.                  52, 55, 57). Mutational analyses trans-acting viral <br /> Despite lack functional activity assay,        polypeptides revealed presence function- mutants stably expressed, assessed Western              ally analogous subregion domains, including arginine-rich <br /> blotting Rev-specific antisera (Fig. 5).                           motif mediating RNA binding nuclear/nucleolar localiza- <br />                                                                         tion C-terminal sequences comprising putative <br />                                                                         activation domain (27, 31, 39, 53).  leucine-rich <br />           12 <br />                                                                         segment activation domain appears functionally <br />                                                                         interchangeable Rex Rev (23, 54). bipartite <br />           10 r                                                          multimerization domain located amino acids 23                                                                         31 54 57, segments immediately flank                                                                         arginine-rich motif, described Rev (28). <br />                                                                         Mutations arginine-rich domains transactiva- <br />                                                                         tors lead recessive negative class mutants lack <br />                                                                         ability bind RNA response elements.             4                                                                                                                                       1    2 3 4 5            6 <br />                                                                                             68          135 <br />                                                                                             43_i- <br />                                                                                            30- <br />                                                                                             18- <br />   FIG. 4. Evidence HIV Rev protein forms apparent <br /> homomultimeric complexes vivo absence RevRE. <br /> COS cells cotransfected various combinations             FIG. 5. Western blotting analysis GAL4-Rev wild-type GAL4 VP16 chimeric expression plasmids pG5BCAT                  mutant protein expression COS cells. Shown results reporter plasmid indicated. level transactivation resulting   GAL4-Rex (lane 1), GAL4-Rev (lane 2), GAL4-Rev M4 (lane 3), coexpression GAL4 Rev-VP16 used             GAL4-Rev M28 (lane 4), GAL4-Rev M33 (lane 5), Rev-VP16 <br /> ground. Data presented correspond mean fold stimulation          (lane 6). Functional results protein-protein interactions levels + standard errors means derived indepen-       various expression vectors shown Table 2. Sizes dent transfection experiments.                                          indicated kilodaltons. <br />  2500     BOGERD GREENE                                                                                                     J. VIROL. <br />  <br /> contrast, mutations C-terminal leucine-rich             vivo protein-protein association limited activation domain result dominant negative mutant pro-           viral transactivator involves bridging <br /> teins retain RNA binding activity (5, 23, 32).            cellular factor. Specifically, cellular protein rep- <br /> Mutations multimerization domain Rev             resent long-elusive host factor proposed variably described producing recessive nega-         bind leucine-rich activation domain Rex tive weakly dominant negative phenotypes (27, 28, 36,            Rev required function viral <br /> 58). analogous multimerization domain Rex         proteins. finding Rex Rev fail associate precisely identified, domain involve       heteromerically vivo indicate cellular <br /> residues inactivated M6 M7 dominant negative             factors interacting viral regulatory proteins Rex mutations located N terminal ex-               distinct.  particularly view fully ex- <br /> changeable leucine-rich activation domain. present,          changeable leucine-rich activation domains (23, 54), precise role multimerization Rex Rev             suspect cellular factor involved biological function remains unknown.               heteromers fail form second structural <br /> likely protein-protein interactions allow        motif, multimerization domain, required fails assembly multiple Rex Rev molecules RNA                support vivo cross-coupling Rex Rev poly- <br /> response element essential interactions            peptides.  importance multimerization cellular cofactors needed Rex Rev function.            domain vivo assembly reaction highlighted    study, demonstrate HTLV Rex           inhibitory effects M4 mutation Rev M6 HIV-1 Rev proteins capable associating living         M7 mutations Rex specify multimer- <br /> cells form apparent homomultimeric complexes              ization domains transactivators. apparent <br /> absence cognate RNA response elements.             lack effects Rev M7 mutation assay transactivators unable cross-             proposed specify downstream portion couple vivo yield stable Rex-Rev heteromultimeric             bipartite multimerization domain Rev brings question <br /> complexes. note, vivo association Rev               true function segment Rev. present, measured CAT-based transcriptional assay            precise role apparent vivo multimerization reac- <br /> sistently weaker detected Rex. present,       tion Rex Rev induction cytoplasmic gag-pol <br /> stoichiometric composition biologically active com-          env mRNA expression remains poorly understood. <br /> plexes Rex Rev remains unclear, native Rev           near complete failure various transdom- reported exist tetramer solution (34, 58).      inant mutants Rex Rev allow assembly <br /> Strikingly, vivo protein-protein interactions      reactions occur vivo argues process likely <br /> Rex Rev consistently disrupted dominant                 central biological action viral trans- <br /> negative point mutations involving multimeriza-          activators.  binding inactive monomers Rex <br /> tion activation domains viral transactivators.      Rev vivo unstable multimers Rex Rev  findings suggest intriguing possibility         lacking critical cellular cofactor single Rex activation dimerization domains Rex        Rev molecules linked cellular cofactor Rev importantly involved protein-protein interactions        Rex Rev molecules underlie transdominant <br /> occurring vivo interactions           phenotype various mutants. prior finding intrinsically linked biological function trans-     transdominant mutants Rev capable multimerizing <br /> activators. Unfortunately, recessive negative mutants            RevRE vitro (28) underestimate dynamics <br /> Rex Rev altered arginine-rich RNA binding              restrictions protein-protein interactions occurring <br /> domains tested assay             vivo. Alternatively, binding Rex Rev chimeric proteins proved consistently unstable ex-             cognate RNA response elements serve stabi- <br /> pressed COS cells.                                               lize interaction, making cellular factor bound    Dominant negative repressor gene products              activation domain important.  binding RNA <br /> identified diverse genetic systems (16, 26, 50).     result release cellular factor <br /> mechanism leading transdominance involves               followed binding different factor activation <br /> assembly inactive mixed multimers, illustrated         domain, providing additional level regulation. Notwith- <br /> dominant negative 1-d mutants prokaryotic lac repres-        standing uncertainties, models argue sor (33).  model proposed                Rex Rev biological action critically involves recruit- <br /> transdominant Rev mutants ability inhibit       ment multiple Rex Rev molecules cellular factors <br /> wild-type Rev action located cytoplasm        RNA response element vivo. nucleus (24).  striking inability transdominant mutants Rex Rev associate vivo                                    REFERENCES appear argue simple model. Alterna-           1. Ahmed, Y. F., S. M. Hanly, M. H. Malim, B. R. Cullen, tively, systems, transdominance shown             W. C. Greene. 1990. Structure-function analyses HTLV reflect occupancy binding site mutant protein           Rex HIV-1 Rev RNA response elements: insights incapable supporting subsequent critical functional            mechanism Rex Rev action. Genes Dev. 4:1014-1022. <br /> step. regard, findings quite consistent    2. Ballard, D. W., E. P. Dixon, N. J. Peffer, H. Bogerd, S. Doerre, <br /> possibility transdominant mutants Rex Rev              B. Stein, W. C. Greene. 1992. 65-kDa subunit human <br /> bind nonfunctional monomers target RNA se-                 NF-KB functions potent transcriptional activator quences vivo incapable undergoing                target v-Rel-mediated repression. Proc. Natl. Acad. Sci. prior subsequent protein assembly reaction obli-           USA 89:1875-1879. <br />                                                                     3. Ballaun, C., G. K. Farrington, M. Dobrovnik, J. Rusche, J. <br /> gately required biological function. findings            Hauber, E. Bohnlein. 1991. Functional analysis human suggest activation domain intimately               T-cell leukemia virus type rex-response element: direct RNA <br /> involved vivo protein-protein interactions.        binding Rex protein correlates vivo activity. J. Virol. <br /> regard, particularly intriguing consider possibility      65:4408-4413. <br />  VOL. 67, 1993                                                   FAILURE Rex Rev MUTANTS MULTIMERIZE                               2501 <br />  <br />  4. Barre-Sinoussi, F., J. C. Chermann, F. Rey, M. T. Nugeyre, S.              human T-cell leukemia virus type trans-acting rex gene prod- <br />      Chamarel, T. Gruest, C. Davguet, C. Axier-Blin, F. Vezin-Brun,            uct. J. Virol. 65:3379-3383. <br />      C. Rouzioux, W. Rozenbaum, L. Montagnier. 1983. Isola-          23.   Hope, T. J., B. L. Bond, D. McDonald, N. P. Klein, T. G. <br />      tion T-lymphocyte retrovirus patient risk              Parslow. 1991. Effector domains human immunodeficiency <br />      acquired immune deficiency syndrome. Science 220:868-870.                 virus type 1 Rev human T-cell leukemia virus type Rex  5. Bogerd, H. P., G. L. Huckaby, Y. F. Ahmed, S. M. Hanly,                functionally interchangeable share essential <span id='am-1' about='obo:IMR_0001700' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001'><span id='am-2' property="rdfs:label" content="peptide" datatype="xsd:string"></span><span id='am-3' property="oboInOwl:id" content="IMR:0001700" datatype="xsd:string"></span><span id='am-4' property="obo:IAO_0000115" content="The polypeptide that is not a gene product." datatype="xsd:string"></span><span id='am-5' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span>peptide</span> <br />      W. C. Greene. 1991. type human T-cell leukemia virus                motif. J. Virol. 65:6001-6007. <br />      (HTLV  Rex trans-activator binds directly HTLV Rex       24.   Hope, T. J., N. P. Klein, M. E. Elder, T. G. Parslow. 1992. <br />      type human immunodeficiency virus Rev RNA response                  trans-dominant inhibition human immunodeficiency virus <br />      elements. Proc. Natl. Acad. Sci. USA 88:5704-5708.                        type 1 Rev occurs formation inactive protein com- <br />   6. Chang, D. D., P.  Sharp. 1989. Regulation HIV Rev                plexes. J. Virol. 66:1849-1855. <br />      depends recognition RNA splice sites. Cell 59:789-795.      25.   Inoue, J. , M. Yoshida, M. Seiki. 1987. Transcriptional <br />   7. Cullen, B. R. 1986. Trans-activation human immunodefi-                 (p40&quot;) post-transcriptional (p27&quot;-&quot;&apos;) regulators required <br />      ciency virus occurs bimodal mechanism. Cell 46:973-982.             expression replication human T-cell leukemia <br />   8. Daly, T. J., K. S. Cook, G. S. Gray, T. E. Malone, J. R.              virus type genes. Proc. Natl. Acad. Sci. USA 84:3653-3657. <br />      Rusche. 1989. Specific binding HIV-1 recombinant Rev         26.   Lanford, R. E., J. S. Butel. 1984. Construction charac- <br />      protein Rev-responsive element vitro. Nature (London)           terization SV40 mutant defective nuclear transport T <br />      342:816-819.                                                              antigen. Cell 37:801-813. <br />   9. Dayton, E., D. Powell,  Dayton. 1989. Functional analysis     27.   Malim, M. H., S. Bohnlein, J. Hauber, B. R. Cullen. 1989. <br />      CAR, target sequence Rev protein HIV-1.                 Functional dissection HIV-1 Rev trans-activator-deriva- <br />      Science 246:1625-1629.                                                    tion trans-dominant repressor Rev function. Cell 58:205- <br /> 10. Fauci,  S. 1988. human immunodeficiency virus: infectiv-             214. <br />      ity mechanisms pathogenesis. Science 239:617-622.            28.   Malim, M. H., B. R. Cullen. 1991. HIV-1 structural gene <br /> 11. Felber, B. K., D. Derse,  Athanassopoulos, M. Campbell,              expression requires binding multiple Rev monomers      G. N. Pavlakis. 1989. Cross-activation rex proteins             viral RRE: implications HIV-1 latency. Cell 65:241-248. <br />      HTLV-1 BLV Rev protein HIV-1                  29.   Malim, M. H., J. Hauber, R. Fenrick, B. R. Cullen. 1988. <br />      nonreciprocal interactions RNA responsive elements.            Immunodeficiency virus rev trans-activator modulates expres- <br />      New Biol. 1:318-330.                                                      sion viral regulatory genes. Nature (London) 335:181- <br /> 12. Fields, S., O.-K. Song. 1989. novel genetic                183. <br />      detect protein-protein interactions. Nature (London) 340:245-       30.   Malim, M. H., J. Hauber, S.-Y. Lee, J. V. Maizel, B. R. <br />      246.                                                                      Cullen. 1989. HIV-1 rev trans-activator acts 13. Gallo, R. C., S.  Salahuddin, M. Popovic, G. M. Shearer, M.              structured target sequence activate nuclear export  <br />      Kaplan, B. F. Haynes, T. J. Palker, R. Redfield, J. Oleske, B.            spliced viral mRNA. Nature (London) 338:254-257. <br />      Sasai, G. White, P. Foster, P. D. Markham. 1984. Frequent       31.   Malim, M. H., D. F. McCarn, L. S. Tiley, B. R. Cullen. <br />      detection isolation cytopathic retroviruses (HTLV-III)             1991. Mutational <span id='am-6' about='obo:IAO_0000115' typeof='owl:Thing'>definition</span> human immunodeficiency <br />      patients AIDS risk AIDS. Science 224:500-             virus type 1 Rev activation domain. J. Virol. 65:4248-4254. <br />      503.                                                                32.   Malim, M. H., L. S. Tiley, D. F. McCarn, J. R. Rusche, J. <br /> 14. Gessain, , F. Barin, J. C. Vernant, 0. Gout, L. Maurs,                 Hauber, B. R. Cullen. 1990. HIV-1 structural gene expres- <br />      Calender, G.  1985. Antibodies human T                  sion requires binding Rev trans-activator RNA <br />      lymphotropic virus type-1 patients tropical spastic               target sequence. Cell 60:675-683. <br />      paraparesis. Lancet ii:407-410.                                     33.   Miller, J. H. 1980. lac gene: role lac operon control <br /> 15. Grassmann, R. S., S. Berchtold, C. Aepinus, C. Ballaun, E.                 use genetic  p. 31-88. J. H. Miller      Bohnlein, B. Fleckenstein. 1991. vitro binding human            W. R. Reznikoff (ed.), operon, 2nd ed. Cold Spring Harbor <br />      T-cell leukemia virus rex proteins rex-response element         Laboratory, Cold Spring Harbor, N.Y. <br />      viral transcripts. J. Virol. 65:3721-3727.                          34.   Nalin, C. M., R. D. Purcell, D. Antelman, D. Mueller, L. <br /> 16. Glenn, G. M., R. P. Ricciardi. 1987. adenovirus type 5              Tomchak, B. Wegrzynski, E. McCarney, V. Toome, R. Kramer, <br />      ElA protein single <span id='am-7' about='obo:IMR_0001695' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001'><span id='am-8' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-9' property="obo:IAO_0000115" content="Organic compounds that generally contain an amino (-NH2) and a carboxyl (-COOH) group. Twenty alpha-amino acids are the subunits which are polymerized to form proteins." datatype="xsd:string"></span><span id='am-10' property="oboInOwl:id" content="IMR:0001695" datatype="xsd:string"></span><span id='am-11' property="oboInOwl:hasDbXref" content="CHEBI:33709" datatype="xsd:string"></span><span id='am-12' property="oboInOwl:hasDbXref" content="MeSH:D000596" datatype="xsd:string"></span><span id='am-13' property="rdfs:label" content="amino acid" datatype="xsd:string"></span>amino acid</span> substitution blocks wild-            M.-C. Hsu. 1990. Purification characterization  <br />      type ElA transactivation. Mol. Cell. Biol. 7:1004-1011.                   combinant Rev protein human immunodeficiency virus type <br /> 17. Greene, W. C., B. R. Cullen. 1990. Rev-Rex connec-                 1. Proc. Natl. Acad. Sci. USA 87:7593-7597. <br />      tion: convergent strategies post-transcriptional regula-    35.   Neumann, J. R., C.  Morency, K. 0. Russian. 1987.      tion HIV-1 HTLV gene expression. Semin. Virol.                   novel rapid assay chloramphenicol acetyl transferase gene <br /> </body></html>